基于细胞因子谱与滑膜组织特征个体化治疗类风湿关节炎:潜力与挑战
本文为叙述性综述,检索PubMed上关于类风湿关节炎疾病活动度和药物反应生物标志物的研究,重点总结血清细胞因子谱及滑膜巨噬细胞和成纤维细胞亚群作为新型生物标志物的关键研究,认为基于这些特征的精准医学方法有望改善患者照护,但尚需更多研究识别可预测药物反应的生物标志物。
要点
- 约40%的类风湿关节炎患者对一线生物改善病情抗风湿药无反应。
- 医生常凭经验试错选择生物改善病情抗风湿药,效率低且成本高。
- 血清细胞因子谱与滑膜巨噬细胞、成纤维细胞亚群是潜在的新型生物标志物。
核心结论
- 基于细胞因子谱和滑膜组织特征制定治疗方案的精准医学新方法有望改善类风湿关节炎患者照护,但尚需更多研究识别可预测药物反应的生物标志物。
研究设计与样本
- 叙述性综述,检索PubMed以识别类风湿关节炎治疗中疾病活动度和药物反应生物标志物的相关研究。
主要发现
- 过去二十年类风湿关节炎治疗取得显著进展,但约40%的患者对一线生物改善病情抗风湿药无反应。
- 医生常采用经验性试错方法为类风湿关节炎患者选择生物改善病情抗风湿药,效率低且对资源有限的医疗系统成本高。
- 与肿瘤学中分子病理指导靶向治疗不同,类风湿关节炎药物反应的可靠预测性生物标志物尚未被识别。
- 综述详细概述了识别血清细胞因子谱及滑膜巨噬细胞和成纤维细胞亚群作为类风湿关节炎疾病活动度和药物反应新型生物标志物的关键研究。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出类风湿关节炎药物反应的可靠预测性生物标志物尚未被识别。
- 原文指出尚需更多研究识别可预测药物反应的生物标志物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Rheumatoid arthritis (RA) is an autoimmune, chronic inflammatory disease that mainly affects the joints and periarticular soft tissues. Although there have been significant advances in RA treatment over the past two decades, approximately 40% of patients do not respond to first-line biological disease-modifying antirheumatic drugs (bDMARDs). Physicians often use an empirical, trial-and-error approach to select bDMARDs to treat patients with RA. This is inefficient and can be costly for healthcare systems which have limited resources. Unlike in oncology, where molecular pathology helps guide targeted therapies, reliable, predictive biomarkers for drug response in RA are yet to be identified. This narrative review aims to summarise current knowledge on novel biomarkers of disease activity and drug response in RA, with a particular focus on serum cytokine profiles and macrophage and fibroblast subsets in synovial tissue. We also highlight key areas of further research that could advance the development of targeted therapies for patients with RA. METHODS: We searched PubMed to identify studies pertaining to biomarkers of disease activity and drug response in the treatment of RA. RESULTS: We present a detailed overview of the key studies that have identified serum cytokine profiles and synovial macrophage and fibroblast subsets as novel biomarkers of disease activity and drug response in RA. CONCLUSION: A novel, evidence-based approach to precision medicine in RA, which involves tailoring treatment based on cytokine profiles and synovial tissue signatures, shows promise for improving patient care. However, more research is needed to identify biomarkers that predict drug response.
引用
- Avouac J, Kay J, Choy E, et al. Personalised treatment of rheumatoid arthritis based on cytokine profiles and synovial tissue signatures: potentials and challenges. Semin Arthritis Rheum. 2025. PMID: 40339302. doi:10.1016/j.semarthrit.2025.152740
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。